Biopharma secures co-development agreement for novel cancer therapies

Biopharmaceutical company, Secarna Pharmaceuticals, has entered into a co-development agreement with research and development company, Firebrand Therapeutics, for novel cancer therapies.

As per the agreement, the companies will leverage Secarna’s LNAplus platform to pursue novel targets playing a key role in cancer metastasis, with Firebrand contributing its expertise in the field.

“This agreement is a significant milestone for Secarna as this co-development project will further validate our approach to develop highly specific, safety-optimised and efficacious antisense oligonucleotide therapies for challenging and previously undruggable targets,” commented Jonas Renz, managing director and co-founder of Secarna Pharmaceuticals. “Antisense oligonucleotides are gaining tremendous momentum following recent drug approvals. With our third generation LNAplus platform, I believe we are on our way to write new chapters in the book of antisense oligonucleotide discovery and development.”

Financial terms of the agreement were not disclosed.